Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
On 7 June, the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (or Aβ) plaques from the brain.
Main Authors: | Giovanna Lalli, Jonathan M Schott, John Hardy, Bart De Strooper |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer Nature
2021-08-01
|
Series: | EMBO Molecular Medicine |
Online Access: | https://doi.org/10.15252/emmm.202114781 |
Similar Items
-
Aducanumab—Hope or Disappointment for Alzheimer’s Disease
by: Karolina Wojtunik-Kulesza, et al.
Published: (2023-02-01) -
Hope or hype? Aducanumab as a magic bullet for Alzheimer’s disease
by: Wei-Jye Lin, et al.
Published: (2022-06-01) -
Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?
by: Vahit Yigit, et al.
Published: (2023-08-01) -
Aducanumab for Alzheimer’s disease: The never‐ending story that nurses should know
by: Joel Petch, et al.
Published: (2021-07-01) -
Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price
by: Pranay Sinha, et al.
Published: (2022-01-01)